MYGN supply chain intelligence for Myriad Genetics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BCDA | BioCardia, Inc. | 72% | Reciprocal relationship from BCDA graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from BCDA graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from BCDA g… |
| BNBX | BNB Plus Corp. | 72% | Reciprocal relationship from BNBX graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from BNBX graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from BNBX g… |
| BNR | Burning Rock Biotech Limited | 72% | Reciprocal relationship from BNR graph: days (1) For the year ended December 31, 2024. The design and performance of OncoScreen ™ Plus and OncoCompass ™ Plus has been endorsed by their adoption in ov… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: and adverse effect on our business, financial condition, results of operations and prospects. Our employees and independent contractors may engage in miscondu… |
| FLGT | Fulgent Genetics, Inc. | 72% | Reciprocal relationship from FLGT graph: , information technology, and service companies may develop and sell competitive tests, which may include informatics analysis, integrated genetic tools, and … |
| GH | Guardant Health, Inc. | 72% | Reciprocal relationship from GH graph: biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018; Caris Life Sciences, Inc.; Tempus AI, … |
| IMNM | Immunome, Inc. | 72% | Reciprocal relationship from IMNM graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from IMNM graph: ay in the future cause a security incident or other interruption that could … |
| IRD | Opus Genetics, Inc. | 72% | Reciprocal relationship from IRD graph: patent application. In addition, such interference, re-examination, opposition, post-grant review, inter partes review, supplemental examination, or revocation… |
| KDK | Kodiak AI, Inc. | 72% | Reciprocal relationship from KDK graph: services or employment agreements that contain non-disclosure and non-use provisions with our employees, consultants, contractors and other third parties. Howe… |
| MCRB | Seres Therapeutics, Inc. | 72% | Reciprocal relationship from MCRB graph: , there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. In additio… |
| NEO | NeoGenomics, Inc. | 72% | Reciprocal relationship from NEO graph: rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities in this market within the laboratory tes… |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: ght. We also could be required to obtain a license from such third party to continue developing, manufacturing and marketing product candidates we may develop… |
| PSNL | Personalis, Inc. | 72% | Reciprocal relationship from PSNL graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from PSNL graph: venue and accounts receivable; in particular, we currently derive a substant… |
| SANA | Sana Biotechnology, Inc. | 72% | Reciprocal relationship from SANA graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from SANA graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from SANA g… |
| TEM | Tempus AI, Inc. | 72% | Reciprocal relationship from TEM graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from TEM graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from TEM grap… |
| VCYT | Veracyte, Inc. | 72% | Reciprocal relationship from VCYT graph: y requirements, which may be subject to change, and our failure to comply with these requirements could substantially harm our business. Certain of our produc… |
| VOR | Vor Biopharma Inc. | 72% | Reciprocal relationship from VOR graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from VOR graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from VOR grap… |
| ZVRA | Zevra Therapeutics, Inc. | 72% | Reciprocal relationship from ZVRA graph: that Corium will dedicate to the development, manufacturing or commercialization of AZSTARYS. Our ability to generate revenue under the AZSTARYS License Agree… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BCDA | BioCardia, Inc. | 72% | Reciprocal relationship from BCDA graph: interruption, our ability to manage our domestic and foreign operations could be impaired, which could materially and adversely affect our results of operatio… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from CTMX g… |
| FLGT | Fulgent Genetics, Inc. | 72% | Reciprocal relationship from FLGT graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from FLGT graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from FLGT g… |
| GH | Guardant Health, Inc. | 72% | Reciprocal relationship from GH graph: biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018; Caris Life Sciences, Inc.; Tempus AI, … |
| IMNM | Immunome, Inc. | 72% | Reciprocal relationship from IMNM graph: -party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business f… |
| IRD | Opus Genetics, Inc. | 72% | Reciprocal relationship from IRD graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from IRD graph: patent application. In addition, such interference, re-examination, opposition… |
| KDK | Kodiak AI, Inc. | 72% | Reciprocal relationship from KDK graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from KDK graph: services or employment agreements that contain non-disclosure and non-use prov… |
| MCRB | Seres Therapeutics, Inc. | 72% | Reciprocal relationship from MCRB graph: , there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. In additio… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | Reciprocal relationship from MGX graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from MGX graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from MGX grap… |
| NEO | NeoGenomics, Inc. | 72% | Reciprocal relationship from NEO graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from NEO graph: rofitability. The market for genetic and molecular testing services is highly … |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: ght. We also could be required to obtain a license from such third party to continue developing, manufacturing and marketing product candidates we may develop… |
| PSNL | Personalis, Inc. | 72% | Reciprocal relationship from PSNL graph: venue and accounts receivable; in particular, we currently derive a substantial portion of our revenue from two of our largest customers, Moderna and the VA M… |
| SANA | Sana Biotechnology, Inc. | 72% | Reciprocal relationship from SANA graph: with or controlled by state actors. If any theft or intrusion affects our technology, data, or intellectual property, the value of such technology, data, or i… |
| TEM | Tempus AI, Inc. | 72% | Reciprocal relationship from TEM graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from TEM graph: who use genomic sequencing services predominantly for the research they are co… |
| VCYT | Veracyte, Inc. | 72% | Reciprocal relationship from VCYT graph: y requirements, which may be subject to change, and our failure to comply with these requirements could substantially harm our business. Certain of our produc… |
| VOR | Vor Biopharma Inc. | 72% | Reciprocal relationship from VOR graph: lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any… |
| ZVRA | Zevra Therapeutics, Inc. | 72% | Reciprocal relationship from ZVRA graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from ZVRA graph: vernment contracts or future orders under existing contracts and civil and c… |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| MYGN-OWNER-ORBIMED-ADVISORS-LLC | ORBIMED ADVISORS LLC | 90% | 13F overlay lists ORBIMED ADVISORS LLC as top holder; 205 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CUE | Cue Biopharma, Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| BDRX | Biodexa Pharmaceuticals Plc | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| HTGC | Hercules Capital, Inc. | 100.00 | 2 | |
| GRAL | GRAIL, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| RXRX | Recursion Pharmaceuticals, Inc. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 1 | ['supplier'] |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 2 | |
| DGX | Quest Diagnostics Incorporated | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 1 | ['spend'] |
| DTIL | Precision BioSciences, Inc. | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| RYTM | Rhythm Pharmaceuticals, Inc. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| EWTX | Edgewise Therapeutics, Inc. | 100.00 | 2 |